Morgan Stanley Cogent Biosciences, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 688,894 shares of COGT stock, worth $5.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

688,894

Previous 981,644 29.82%

Holding current value

$5.43 Million

Previous $8.28 Million 10.09%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.24 - $11.48 $2.41 Million - $3.36 Million	-292,750 Reduced 29.82%	688,894 $7.44 Million
Q2 2024 Oct 17, 2024	SELL	$6.01 - $9.04 $5.22 Million - $7.86 Million	-869,072 Reduced 46.96%	981,644 $8.28 Million
Q2 2024 Aug 14, 2024	SELL	$6.01 - $9.04 $5.22 Million - $7.86 Million	-869,072 Reduced 46.96%	981,644 $8.28 Million
Q1 2024 Oct 17, 2024	BUY	$4.38 - $9.02 $3.81 Million - $7.84 Million	869,072 Added 88.53%	1,850,716 $12.4 Million
Q1 2024 Aug 16, 2024	SELL	$4.38 - $9.02 $1.79 Million - $3.68 Million	-408,485 Reduced 18.08%	1,850,716 $12.4 Million
Q1 2024 May 15, 2024	SELL	$4.38 - $9.02 $1.79 Million - $3.68 Million	-408,485 Reduced 18.08%	1,850,716 $12.4 Million
Q4 2023 Aug 16, 2024	BUY	$4.06 - $10.08 $5.19 Million - $12.9 Million	1,277,557 Added 130.14%	2,259,201 $13.3 Million
Q4 2023 Feb 13, 2024	BUY	$4.06 - $10.08 $8.65 Million - $21.5 Million	2,129,702 Added 1644.57%	2,259,201 $13.3 Million
Q3 2023 Nov 15, 2023	SELL	$9.69 - $13.34 $413,530 - $569,297	-42,676 Reduced 24.79%	129,499 $1.26 Million
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.24 $743,625 - $999,553	-75,495 Reduced 30.48%	172,175 $2.04 Million
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $2.45 Million - $3.78 Million	-243,767 Reduced 49.6%	247,670 $2.67 Million
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $784,713 - $1.09 Million	-73,682 Reduced 13.04%	491,437 $5.68 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $2.7 Million - $4.89 Million	287,972 Added 103.91%	565,119 $8.43 Million
Q2 2022 Oct 27, 2022	BUY	$3.92 - $9.73 $1.02 Million - $2.53 Million	260,126 Added 1528.27%	277,147 $2.5 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $1.02 Million - $2.53 Million	260,126 Added 1528.27%	277,147 $2.5 Million
Q1 2022 Oct 27, 2022	SELL	$5.31 - $8.7 $1.38 Million - $2.26 Million	-260,126 Reduced 93.86%	17,021 $128,000
Q1 2022 May 13, 2022	SELL	$5.31 - $8.7 $4,083 - $6,690	-769 Reduced 4.32%	17,021 $128,000
Q4 2021 Feb 14, 2022	BUY	$7.51 - $10.81 $72,261 - $104,013	9,622 Added 117.8%	17,790 $153,000
Q3 2021 Nov 15, 2021	BUY	$5.99 - $9.14 $48,926 - $74,655	8,168 New	8,168 $68,000

Others Institutions Holding COGT

# of Institutions

172

Shares Held

113M

Call Options Held

56.7K

Put Options Held

40.4K

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $518M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account